A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1794, Issue 4, 2009, Pages 615-626

  Bottoni, Patrizia ^a   Giardina, Bruno ^a   Vitali, Alberto ^b   Boninsegna, Alma ^a   Scatena, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CNR   (Italy)

Author keywords

Biomarker; Cancer; Cell differentiation; Diagnostics; Mitochondria; Oncoproteomics; Stress protein

Indexed keywords

CIGLITAZONE;

AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PPAR GAMMA; PROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THIAZOLIDINEDIONES; TUMOR MARKERS, BIOLOGICAL;

EID: 61649090194     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.01.006     Document Type: Article

References (74)

1. Seow T.K., Liang R.C., Leow C.K., and Chung M.C. Hepatocellular carcinoma: from bedside to proteomics. Proteomics 10 (2001) 1249-1263
2. Sun W., Xing B., Sun Y., Du X., Lu M., Hao C., Lu Z., Mi W., Wu S., Wei H., Gao X., Zhu Y., Jiang Y., Qian X., and He F. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell Proteomics 6 (2007) 1798-1808
3. Wu N., Zhang W., Yang Y., Liang Y.L., Wang L.Y., Jin J.W., Cai X.M., and Zha X.L. Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics 22 (2006) 6095-6106
4. Zhang D., Lim S.G., and Koay E.S. Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma. Int. J. Oncol. 31 (2007) 577-584
5. Santamaria E., Munoz J., Fernandez-Irigoyen J., Prieto J., and Corrales F.J. Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int. 27 (2007) 163-173
6. Burroughs A., Hochhauser D., and Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 5 (2004) 409-418
7. Samonakis D.N., Moschandreas J., Arnaoutis T., Skordilis P., Leontidis C., Vafiades I., and Kouroumalis E. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol. Rep. 9 (2002) 903-907
8. Scatena R., Bottoni P., and Giardina B. Modulation of cancer cell line differentiation: a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteom. Clin. Appl. 2 (2008) 229-237
9. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health disease. Nature 405 (2000) 421-424
10. Lazar M.A. Progress in cardiovascular biology: PPAR for the course. Nat. Med. 7 (2001) 23-24
11. Gale E.A. Lessons from the glitazones: a story of drug development. Lancet 357 (2001) 1870-1875
12. Scatena R., Nocca G., De Sole P., Rumi C., Puggioni P., Remiddi F., Bottoni P., Ficarra S., and Giardina B. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ. 6 (1999) 781-787
13. Harman F.S., Nicol C.J., Marin H.E., Ward J.M., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-d attenuates colon carcinogenesis. Nat. Med. 10 (2004) 481-483
14. Michalik L., Desvergne B., and Wahli W. Peroxisome proliferator-activated receptor and cancers: complex stories. Nat. Rev. Cancer 4 (2004) 61-70
15. Palakurthi S.S., Aktas H., Grubissich L.M., Mortensen R.M., and Halperin J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor g and mediated by inhibition of translation initiation. Cancer Res. 61 (2001) 6213-6218
16. Scatena R., Bottoni P., Vincenzoni F., Messana I., Martorana G.E., Nocca G., De Sole P., Maggiano N., Castagnola M., and Giardina B. Bezafibrate induces a mitochondrial derangement in human cell lines. Intriguing effects for a peroxisome proliferator. Chem. Res. Tox. 16 (2003) 1440-1447
17. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K., and DuBois R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 10 (2004) 245-247
18. Bottoni P., Giardina B., Martorana G.E., Zuppi C., De Sole P., Rossi C., and Scatena R. A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. J. Cell Mol. Med. 9 (2005) 462-467
19. Feng J.T., Shang S., and Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 25 (2006) 3810-3817
20. Zhou G., Li H., DeCamp D., Chen S., Shu H., Gong Y., Flaig M., Gillespie J.W., Hu N., Taylor P.R., Emmert-Buck M.R., Liotta L.A., Petricoin E.F., and Zhao Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell Proteomics 1 (2002) 117-124
21. Marks P.A., and Rifkind R.A. Differentiating factors. In: De Vita V.T., Hellmann S., and Rosenberg S.A. (Eds). Cancer: Principles and Practice Oncology. 6th ed. (2001), J. B. Lippincott Company, Philadelphia 754-762
22. Knowles B.B., Howe C.C., and Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209 (1980) 497-499
23. Yasuda I., Shiratori Y., Adachi S., Obora A., Takemura M., Okuno M., Shidoji Y., Seishima M., Muto Y., and Moriwaki H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J. Hepatol. 36 (2002) 660-671
24. Kelly J.H., and Darlington G.J. Modulation of the liver specific phenotype in the human hepatoblastoma line HepG2. In Vitro Cell. Dev. Biol. 25 (1989) 217-222
25. Bouma M.E., Rogier E., Verthier N., Labarre C., and Feldmann G. Further cellular investigation of the human hepatoblastoma-derived cell line HepG2: morphology and immunocytochemical studies of hepatic-secreted proteins. In Vitro Cell. Dev. Biol. 25 (1989) 267-275
26. Chou J.Y., and Schlegel-Haueter S.E. Study of liver differentiation in vitro. J. Cell Biol. 89 2 (1981) 216-222
27. Nohara T. Establishment of an AFP-producing serum-independent culture cell line of human liver cancer and changes in protein synthesis associated with the absence of serum (second part). Gastroenterol Jpn. 23 (1988) 23-28
28. Cho W. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2 (2007) 6-25
29. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., Thomazy V.A., and Evans R.M. Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat. Med. 4 (1998) 1058-1061
30. Lefebvre A.M., Chen I., Desreumaux P., Najib J., Fruchart J.C., Geboes K., Briggs M., Heyman R., and Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4 (1998) 1053-1057
31. Nagakubo D., Taira T., Kitaura H., Ikeda M., Tamai K., Iguchi-Ariga S.M., and Ariga H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231 (1997) 509-513
32. Kim R.H., Peters M., Jang Y., Shi W., Pintilie M., Fletcher G.C., DeLuca C., Liepa J., Zhou L., Snow B., Binari R.C., Manoukian A.S., Bray M.R., Liu F.F., Tsao M.S., and Mak T.W. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 7 (2005) 263-273
33. Fan J., Ren H., Jia N., Fei E., Zhou T., Jiang P., Wu M., and Wang G. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J. Biol. Chem. 7 (2008) 4022-4030
34. MacKeigan J.P., Clements C.M., Lich J.D., Pope R.M., Hod Y., and Ting J.P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 63 (2003) 6928-6934
35. Taira T., Saito Y., Niki T., and Iguchi-Ariga S.M. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5 (2004) 213-218
36. Yokota T., Sugawara K., Ito K., Takahashi R., Ariga H., and Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 312 (2003) 1342-1348
37. Clements C.M., McNally R.S., Conti B.J., Mak T.W., and Ting J.P. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15091-15096
38. Zhou W., Zhu M., Wilson M.A., Petsko G.A., and Fink A.L. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol. 356 (2006) 1036-1048
39. Rhee S.G. H2O2, a necessary evil for cell signaling. Science 312 (2006) 1882-1883
40. Ai J., Tan Y., Ying W., Hong Y., Liu S., Wu M., Qian X., and Wang H. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics 6 (2006) 538-546
41. Neumann C.A., and Fang Q. Are peroxiredoxins tumor suppressors?. Curr. Opin. Pharmacol. 7 (2007) 375-380
42. Feurestein N., and Cooper H.L. Rapid protein phosphorylation induced by phorbol ester in HL-60 cells. Unique alkali-stable phosphorylation of a 17,000-dalton protein detected by two-dimensional gel electrophoresis. J. Biol. Chem. 258 (1983) 10786-10793
43. Kouzu Y., Uzawa K., Koike H., Saito K., Nakashima D., Higo M., Endo Y., Kasamatsu A., Shiiba M., Bukawa H., Yokoe H., and Tanzawa H. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br. J. Cancer 94 (2006) 717-723
44. Li C., Tan Y.X., Zhou H., Ding S.J., Li S.J., Ma D.J., Man X.B., Hong Y., Zhang L., Li L., Xia Q.C., Wu J.R., Wang H.Y., and Zeng R. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: identification of potential tumor markers. Proteomics 5 (2005) 1125-1139
45. Yuan R.H., Jeng Y.M., Chen H.L., Lai P.L., Pan H.W., Hsieh F.J., Lin C.Y., Lee P.H., and Hsu H.C. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J. Pathol. 209 (2006) 549-558
46. Chen Y., Lin M.C., Wang H., Chan C.Y., Jiang L., Ngai S.M., Yu J., He M.L., Shaw P.C., Yew D.T., Sung J.J., and Kung H.F. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma. Proteomics 7 (2007) 3097-3104
47. Mistry S.J., and Atweh G.F. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt. Sinai J. Med. 69 (2002) 299-304
48. Kinoshita I., Leaner V., Katabami M., Manzano R.G., Dent P., Sabichi A., and Birrer M.J. Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth. Oncogene 22 (2003) 2710-2722
49. Alli E., Yang J.M., and Hait W.N. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26 (2007) 1003-1012
50. Terada K., Manchikalapudi P., Noiva R., Jauregui H.O., Stockert R.J., and Schilsky M.L. Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. J. Biol. Chem. 270 (1995) 20410-20416
51. Mandel R., Ryser H.J., Ghani F., Wu M., and Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 4112-4116
52. Lahav J., Gofer-Dadosh N., Luboshitz J., Hess O., and Shaklai M. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett. 475 (2000) 89-92
53. Lahav J., Lahav J., Jurk K., Hess O., Barnes M.J., Farndale R.W., Luboshitz J., and Kehrel B.E. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 100 (2002) 2472-2478
54. Updike M.S., Sawdy J.C., Wang L.S., Liu S., Huang Y.W., Ye W., Farrar W.B., Lin Y.C., and Wick M. Primary cultured human breast epithelial cells up-regulate protein disulfide isomerase in response to zeranol. Anticancer Res. 27 (2007) 407-410
55. Goplen D., Wang J., Enger P.O., Tysnes B.B., Terzis A.J., Laerum O.D., and Bjerkvig R. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 66 (2006) 9895-9902
56. Stierum R., Gaspari M., Dommels Y., Ouatas T., Pluk H., Jespersen S., Vogels J., Verhoeckx K., Groten J., and van Ommen B. Proteome analysis reveals novel proteins associated with proliferation and differentiation of the colorectal cancer cell line Caco-2. Biochim. Biophys. Acta 1650 (2003) 73-91
57. Monig S.P., Nolden B., Lubke T., Pohl A., Grass G., Schneider P.M., Dienes H.P., Holscher A.H., and Baldus S.E. Clinical significance of nm23 gene expression in gastric cancer. Anticancer Res. 4C (2007) 3029-3033
58. Zimmerman R.L., and Fogt F. NM23 is expressed in reactive mesothelium and is not useful for detection of malignant cells in serous effusions. Oncol. Rep. 1 (2006) 85-88
59. Lin L.I., Lee P.H., Wu C.M., and Lin J.K. Significance of nm23 mRNA expression in human hepatocellular carcinoma. Anticancer Res. 18 (1998) 541-546
60. D'Souza R.J., Sheikh Z.A., Busund L.T., Russell P.J., Crowe P.J., and Yang J.L. Expression of nm23 protein in adult soft tissue sarcoma is correlated with histological grade. Anticancer Res. 23 (2003) 3289-3294
61. Scatena R., Bottoni P., Martorana G.E., Vincenzoni F., Botta G., Pastore P., and Giardina B. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. Eur. J. Pharmacol. 567 (2007) 50-58
62. Howard B.A., Furumai R., Campa M.J., Rabbani Z.N., Vujaskovic Z., Wang X.F., and Patz E.F. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 65 (2005) 8853-8860
63. Shen J., Person M.D., Zhu J., Abbruzzese J.L., and Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64 (2004) 9018-9026
64. Fillies T., Werkmeister R., van Diest P.J., Brandt B., Joos U., and Buerger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5 (2005) 84
65. Li M., Zhai Q., Bharadwaj U., et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 106 (2006) 2284-2294
66. Yang H., Chen J., Yang J., Qiao S., Zhao S., and Yu L. Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem. Biophys. Res. Commun. 361 (2007) 63-67
67. Shimada K., Uzawa K., Kato M., et al. Aberrant expression of RAB1A in human tongue cancer. Br. J. Cancer 92 (2005) 1915-1921
68. Dabbeekeh J.T., Faitar S.L., Dufresne C.P., and Cowell J.K. The EVI5 TBC domain provides the GTPase-activating protein motif for RAB11. Oncogene 26 (2007) 2804-2808
69. Schuierer M.M., Bataille F., Weiss T.S., Hellerbrand C., and Bosserhoff A.K. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep. 16 (2006) 451-456
70. Kojima K., Konopleva M., Samudio I.J., Ruvolo V., and Andreeff M. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res. 67 (2007) 3210-3219
71. Kim J.W., and Dang C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem Sci. 30 (2005) 142-150
72. Feo S., Arcuri D., Piddini E., Passantino R., and Giallongo A. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett. 473 (2000) 47-52
73. Calderwood S.K., Khaleque M.A., Sawyer D.B., and Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31 (2006) 164-172
74. Calderwood S.K. Chaperones and slow death-a recipe for tumor immunotherapy. Trends Biotechnol. 23 (2005) 57-59